This page contains brief information about belzutifan (Welireg) and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.
FDA label information for this drug is available at DailyMed.
Use in Cancer
Belzutifan is approved to treat adults with:
- Cancers linked to Von Hippel-Lindau disease that require treatment but not immediate surgery, including:
- Central nervous system hemangioblastoma.
- Pancreatic neuroendocrine tumors.
- Renal cell carcinoma.
Belzutifan is also being studied in the treatment of other types of cancer.
More About Belzutifan
Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.
MedlinePlus Information on Belzutifan - A lay language summary of important information about this drug that may include the following:
- warnings about this drug,
- what this drug is used for and how it is used,
- what you should tell your doctor before using this drug,
- what you should know about this drug before using it,
- other drugs that may interact with this drug, and
- possible side effects.
Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.
Research Results and Related Resources
Belzutifan Approved to Treat Tumors Linked to Inherited Disorder VHL
Clinical Trials Accepting Patients
Find Clinical Trials for Belzutifan - Check for trials from NCI's list of cancer clinical trials now accepting patients.